表紙
市場調査レポート

主要先進国における2型糖尿病治療薬市場:強力なパイプラインと治療人口の拡大が堅固な成長を促進

Type 2 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 - Strong Pipeline and Expanding Treatment Population to Encourage Robust Growth

発行 GBI Research 商品コード 336893
出版日 ページ情報 英文 179 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
主要先進国における2型糖尿病治療薬市場:強力なパイプラインと治療人口の拡大が堅固な成長を促進 Type 2 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 - Strong Pipeline and Expanding Treatment Population to Encourage Robust Growth
出版日: 2015年07月03日 ページ情報: 英文 179 Pages
概要

2型糖尿病は、慢性高血糖 (高血糖値) を特徴とする代謝性疾患です。世界の有病率は、この数十年で急速に上昇していますが、特に肥満と合致して増加しています。

当レポートでは、主要先進国における2型糖尿病治療薬市場について調査分析し、市場の概要、上市製品、パイプライン製品、市場予測、取引と戦略的統合などについて、体系的な情報を提供しています。

第1章 目次

第2章 イントロダクション

  • 疾患の概要
  • 疫学
  • 症状
  • 病因
  • 病態生理
  • 併存疾患と合併症
  • 分類
  • 予後
  • 診断
  • 治療効果の評価
  • 治療アルゴリズム
  • 非インスリン2型糖尿病治療
  • インスリン2型糖尿病治療
  • 治療セグメント

第3章 上市製品

  • 概要
  • ビグアニド
  • スルホニル尿素
  • GLP-1受容体作用薬
  • DPP-4阻害剤
  • SGLT-2阻害剤
  • インスリン療法
  • 上市製品のヒートマップ

第4章 パイプライン

  • 概要
  • パイプライン分布:開発段階別、分子タイプ・プログラムタイプ別
  • パイプライン分布:分子標的別
  • 臨床試験の状況
    • 失敗率
    • 期間
    • 臨床試験の規模
  • 有望なパイプライン分子
  • パイプライン製品のヒートマップと競合製品の枠組み

第5章 市場予測

  • 地域市場
  • 世界市場
  • 北米
  • 欧州市場の主要5ヶ国
  • 日本
  • 促進要因と障壁

第6章 戦略的統合

  • ライセンス取引
  • 共同開発取引

第7章 付録

図表

目次
Product Code: GBIHC366MR

Executive Summary

Type 2 Diabetes Mellitus (T2DM) is a metabolic disease characterized by chronic hyperglycemia (high blood glucose levels). Global prevalence has risen rapidly in the past several decades, particularly in line with obesity. This has been attributed to a range of factors, including economic development, increasing urbanization, aging populations, and changes in lifestyle patterns such as reduced levels of physical activity and consumption of higher-calorie diets.

This has led to strong commercial interest in the development of T2DM therapeutics. The current market is large and diverse, comprising several drug classes, including generic and branded drugs. Owing to the range of therapeutic options available, the treatment algorithm is complex. However, current treatment regimens are often associated with limited long-term efficacy, complex and inconvenient dosing regimens, and undesirable side effects such as weight gain and hypoglycemia (low blood glucose levels).

Scope

  • Metformin monotherapy will remain the first-line pharmacotherapy for T2DM.
  • The emergence of several new drug classes over the past decade, namely the Glucagon-Like Peptide-1 (GLP-1) receptor agonists, Dipeptidyl Peptidase 4 (DPP-4) inhibitors, and Sodium-Glucose Cotransporter 2 (SGLT-2) inhibitors, has led to considerable market growth.
  • Which products lead these drug classes and what threats do they face from the pipeline?
  • How will the continued uptake of newer drug classes impact established drug classes such as the sulfonylureas and thiazolidinediones?
  • Leading insulin therapy Lantus (insulin glargine) recently lost patent protection in most major markets.
  • Will recently approved insulin therapies such as Tresiba (insulin degludec) and Toujeo (insulin glargine) be able to capture a significant portion of Lantus' market share?
  • The pipeline is large and highly innovative, comprising a range of molecule types and molecular targets.
  • How do different molecule types and molecular targets compare in terms of average failure rate, clinical trial duration, and clinical trial size?
  • Which late-stage pipeline molecules show the most promise and how will they impact the treatment algorithm over the forecast period?
  • Which late-stage pipeline molecules are expected to generate the highest revenues?
  • Over the 2014-2021 forecast period, the global T2DM market is expected to increase in value at a CAGR of 7.5% from $23.5 billion to $39.0 billion.
  • How do prevalence, diagnosis, and treatment patterns vary in the eight major markets?
  • Which factors will drive market growth most significantly?
  • Strategic consolidation activity in T2DM is considerable, with US-based companies being key players.
  • Do T2DM products tend to attract high levels of investment?

Reasons to buy

  • Understand the clinical context of the T2DM indication and the global burden of the disease by considering epidemiology, symptoms, etiology, pathophysiology, co-morbidities and complications, disease classification, disease prognosis, and treatment options
  • Appreciate the current T2DM marketed products landscape, including the dominant therapeutic strategies, products, and companies, and recognize gaps within the market and areas of unmet need
  • Identify key pipeline trends in molecule type and molecular target
  • Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in T2DM by examining clinical trial data and multi-scenario product forecast projections
  • Consider market opportunities and potential risks by examining trends in T2DM clinical trial size, duration, and failure rate by phase of development, molecule type, and molecular target
  • Discern variances in treatment usage patterns, annual therapy costs, and market growth projections for the US, Canada, the UK, France, Germany, Italy, Spain, and Japan
  • Discover how strategic consolidations have shaped the current T2DM pipeline and marketed products landscapes

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Disease Overview
  • 2.2. Epidemiology
  • 2.3. Symptoms
  • 2.4. Etiology
  • 2.5. Pathophysiology
  • 2.6. Co-morbidities and Complications
  • 2.7. Classification
  • 2.8. Prognosis
  • 2.9. Diagnosis
  • 2.10. Assessing Treatment Effectiveness
  • 2.11. Treatment Algorithm
  • 2.12. Non-insulin T2DM Therapies
    • 2.12.1. Biguanides
    • 2.12.2. Sulfonylureas and Meglitinides
    • 2.12.3. Thiazolidinediones
    • 2.12.4. Glucagon-Like Peptide-1(GLP-1) Receptor Agonists and Dipeptidyl Peptidase 4(DPP-4) Inhibitors
    • 2.12.5. Sodium-Glucose Linked Transporter-2(SGLT-2) Inhibitors
    • 2.12.6. Other Non-insulin Therapies
  • 2.13. Insulin T2DM Therapies
  • 2.14. Treatment Segments
    • 2.14.1. Non-insulin therapies
    • 2.14.2. Insulin Therapies

3. Marketed Products

  • 3.1. Overview
  • 3.2. Biguanides
    • 3.2.1. Metformin - Various Companies
  • 3.3. Sulfonylureas
  • 3.4. Thiazolidinediones
    • 3.4.1. Actos (pioglitazone) - Takeda
  • 3.5. GLP-1 receptor agonists
    • 3.5.1. Byetta (exenatide) - AstraZeneca
    • 3.5.2. Bydureon (exenatide) - AstraZeneca
    • 3.5.3. Victoza (liraglutide) - Novo Nordisk
    • 3.5.4. Tanzeum (albiglutide) - GlaxoSmithKline
    • 3.5.5. Trulicity (dulaglutide) - Eli Lilly
  • 3.6. DPP-4 Inhibitors
    • 3.6.1. Januvia (sitagliptin) - Merck
    • 3.6.2. Galvus (vildagliptin) - Novartis
    • 3.6.3. Onglyza (saxagliptin) - AstraZeneca
    • 3.6.4. Tradjenta (linagliptin) - Boehringer Ingelheim
    • 3.6.5. Zafatek (trelagliptin succinate) - Takeda
  • 3.7. SGLT-2 Inhibitors
    • 3.7.1. Farxiga (dapagliflozin) - AstraZeneca
    • 3.7.2. Invokana (canagliflozin) - Janssen
    • 3.7.3. Jardiance (empagliflozin) - Boehringer Ingelheim
  • 3.8. Insulin Therapies
    • 3.8.1. Lantus (insulin glargine) - Sanofi
    • 3.8.2. Levemir (insulin detemir) - Novo Nordisk
    • 3.8.3. Tresiba (insulin degludec) - Novo Nordisk
    • 3.8.4. Toujeo (insulin glargine) - Sanofi
  • 3.9. Marketed Products Heat Maps

4. Pipeline

  • 4.1. Overview
  • 4.2. Pipeline Distribution by Stage of Development, Molecule Type and Program Type
  • 4.3. Pipeline Distribution by Molecular Target
  • 4.4. Clinical Trial Landscape
    • 4.4.1. Clinical Trial Failure Rates
    • 4.4.2. Clinical Trial Duration
    • 4.4.3. Clinical Trial Size
  • 4.5. Promising Pipeline Molecules
    • 4.5.1. Omarigliptin - Merck
    • 4.5.2. NN-9535 (semaglutide) and OG-217SC (semaglutide) - Novo Nordisk
    • 4.5.3. ITCA 650 - Intarcia Therapeutics
    • 4.5.4. LX-4211 (sotagliflozin) - Lexicon Pharmaceuticals
    • 4.5.5. Insulin peglispro - Eli Lilly and Company
    • 4.5.6. ISIS-GCGRRx - Isis Pharmaceuticals
    • 4.5.7. BSN-175 (D-Tagatose) - Biospherics.net Incorporated
  • 4.6. Pipeline Products Heat Map and Competitive Product Framework

5. Market Forecast to 2021

  • 5.1. Geographical Markets
  • 5.2. Global Markets
  • 5.3. North America
    • 5.3.1. Treatment Usage Patterns
    • 5.3.2. Annual Cost of Therapy
    • 5.3.3. Market Size
  • 5.4. Top Five European Markets
    • 5.4.1. Treatment Usage Patterns
    • 5.4.2. Annual Cost of Therapy
    • 5.4.3. Market Size
  • 5.5. Japan
    • 5.5.1. Treatment Usage Patterns
    • 5.5.2. Annual Cost of Therapy
    • 5.5.3. Market Size
  • 5.6. Drivers and Barriers for the T2DM Therapeutics Market
    • 5.6.1. Drivers
    • 5.6.2. Barriers

6. Strategic Consolidations

  • 6.1. Licensing Deals
    • 6.1.1. Sanofi Enters into Licensing Agreement with MannKind for Afrezza
    • 6.1.2. Array BioPharma Enters into a Licensing Agreement with Amgen - Now Terminated
    • 6.1.3. Emisphere Technologies Enters into a Licensing Agreement with Novo Nordisk
    • 6.1.4. Eli Lilly Enters into Licensing Agreement with Adocia
    • 6.1.5. Depomed Enters into a Licensing Agreement with Merck
  • 6.2. Co-development Deals
    • 6.2.1. Intarcia Therapeutics Enters into Co-Development Agreement with Les Laboratoires Servier for ITCA 650(exenatide)
    • 6.2.2. Merck Enters into Co-Development Agreement with Pfizer for PF-04971729(ertugliflozin)
    • 6.2.3. Eli Lilly Enters into a Co-development Agreement with Boehringer Ingelheim
    • 6.2.4. Amylin Pharma Terminates Co-development Agreement with Eli Lilly for Exenatide
    • 6.2.5. AstraZeneca Enters into Co-development Agreement with Bristol-Myers Squibb
    • 6.2.6. Neurocrine Biosciences Enters into a Collaboration Agreement with Boehringer Ingelheim

7. Appendix

  • 7.1. All Pipeline Drugs by Phase of Development
    • 7.1.1. Discovery
    • 7.1.2. Preclinical
    • 7.1.3. IND/CTA-filed
    • 7.1.4. Phase I
    • 7.1.5. Phase II
    • 7.1.6. Phase III
    • 7.1.7. Pre-registration
  • 7.2. Market Forecasts to 2021
    • 7.2.1. Global
    • 7.2.2. US
    • 7.2.3. Canada
    • 7.2.4. UK
    • 7.2.5. France
    • 7.2.6. Germany
    • 7.2.7. Italy
    • 7.2.8. Spain
    • 7.2.9. Japan
  • 7.3. References
  • 7.4. References for Heat Maps
    • 7.4.1. Marketed Products Heat Map
    • 7.4.2. Pipeline Heat Map
  • 7.5. Abbreviations
  • 7.6. Research Methodology
  • 7.7. Secondary Research
  • 7.8. Marketed Product Profiles
  • 7.9. Late-Stage Pipeline Candidates
  • 7.10. Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
  • 7.11. Product Competitiveness Framework
  • 7.12. Pipeline Analysis
    • 7.12.1. Overall Pipeline
    • 7.12.2. Clinical Trials
    • 7.12.3. Failure Rate
    • 7.12.4. Clinical Trial Size
    • 7.12.5. Clinical Trial Duration
    • 7.12.6. Clinical Trial Endpoint Analysis
  • 7.13. Forecasting Model
  • 7.14. Deals Data Analysis
  • 7.15. Expert Panel Validation
  • 7.16. Contact Us
  • 7.17. Disclaimer

List of Tables

  • Table 1: Dose Levels for Groups Initially Receiving Metformin in Combination with Glyburide, Metformin Monotherapy and Glyburide Monotherapy
  • Table 2: T2DM Therapeutics Market, Global, Breakdown of Multiple Molecular Targets, 2015
  • Table 3: T2DM Therapeutics Market, Global, Breakdown of 'Other' Molecular Targets, 2015
  • Table 4: T2DM Therapeutics, Global, All Pipeline Products, Discovery Phase, 2015
  • Table 5: T2DM Therapeutics, Global, All Pipeline Products, Preclinical Phase, 2015
  • Table 6: T2DM Therapeutics, Global, All Pipeline Products, IND/CTA-filed Phase, 2015
  • Table 7: T2DM Therapeutics, Global, All Pipeline Products, Phase I, 2015
  • Table 8: T2DM Therapeutics, Global, All Pipeline Products, Phase II, 2015
  • Table 9: T2DM Therapeutics, Global, All Pipeline Products, Phase III, 2015
  • Table 10: T2DM Therapeutics, Global, All Pipeline Products, Pre-registration Phase, 2015
  • Table 11: T2DM Therapeutics Market, Global, Market Forecast, 2014-2021
  • Table 12: T2DM Therapeutics Market, US, Market Forecast, 2014-2021
  • Table 13: T2DM Therapeutics Market, Canada, Market Forecast, 2014-2021
  • Table 14: T2DM Therapeutics Market, UK, Market Forecast, 2014-2021
  • Table 15: T2DM Therapeutics Market, France, Market Forecast, 2014-2021
  • Table 16: T2DM Therapeutics Market, Germany, Market Forecast, 2014-2021
  • Table 17: T2DM Therapeutics Market, Italy, Market Forecast, 2014-2021
  • Table 18: T2DM Therapeutics Market, Spain, Market Forecast, 2014-2021
  • Table 19: T2DM Therapeutics Market, Japan, Market Forecast, 2014-2021

List of Figures

  • Figure 1: T2DM Therapeutics Market, Global, Heat Map for Marketed Products, 2015
  • Figure 2: T2DM Therapeutics Market, Global, Heat Map for Marketed Products, 2015 (continued)
  • Figure 3: T2DM Therapeutics Market, Global, Pipeline, 2015
  • Figure 4: T2DM Therapeutics Market, Global, Pipeline by Molecular Target, 2015
  • Figure 5: T2DM Therapeutics Market, Global, Pipeline by Molecular Target, Breakdown of GPCR Molecular Targets, 2015
  • Figure 6: T2DM Therapeutics Market, Global, Pipeline by Molecular Target, Breakdown of Protein Kinase Molecular Targets, 2015
  • Figure 7: T2DM Therapeutics Market, Global, Clinical Trial Failure Rates and Reasons for Failure, 2006-2015
  • Figure 8: T2DM Therapeutics Market, Global, Clinical Trial Failure Rate by Molecule Type, 2006-2015
  • Figure 9: T2DM Therapeutics Market, Global, Clinical Trial Failure Rate by Molecular Target, 2006-2015
  • Figure 10: T2DM Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type, (months), 2006-2015
  • Figure 11: T2DM Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target, (months), 2006-2015
  • Figure 12: T2DM Therapeutics Market, Global, Clinical Trial Recruitment Size by Stage of Development and Molecule Type, (participants), 2006-2015
  • Figure 13: T2DM Therapeutics Market, Global, Clinical Trial Recruitment Size by Stage of Development and Molecular Target, (participants), 2006-2015
  • Figure 14: T2DM Mellitus Therapeutics Market, Global, Cumulative Clinical Trial Recruitment Size by Stage of Development and Molecule Type, (participants), 2006-2015
  • Figure 15: T2DM Therapeutics Market, Global, Cumulative Clinical Trial Recruitment Size by Stage of Development and Molecular Target, (participants), 2006-2015
  • Figure 16: T2DM Therapeutics Market, Global, Omarigliptin Forecast ($m), 2015-2021
  • Figure 17: T2DM Therapeutics Market, Global, Semaglutide Products Forecast ($bn), 2017-2021
  • Figure 18: T2DM Therapeutics Market, Global, ITCA-650 Forecast ($m), 2017-2021
  • Figure 19: T2DM Therapeutics Market, Global, LX-4211 Forecast ($m), 2018-2021
  • Figure 20: T2DM Therapeutics Market, Global, insulin peglispro Forecast ($m), 2018-2021
  • Figure 21: T2DM Therapeutics Market, Global, ISIS-GCGRRx Forecast ($m), 2020-2021
  • Figure 22: T2DM Therapeutics Market, Global, BSN-175 Forecast ($m), 2018-2021
  • Figure 23: T2DM Market, Global, Heat Map for Pipeline Products, 2015
  • Figure 24: T2DM Therapeutics Market, Global, Competitiveness Framework for Marketed and Pipeline Products, 2015
  • Figure 25: T2DM Therapeutics Market, Global, Treatment Usage Patterns, 2014-2021
  • Figure 26: T2DM Therapeutics Market, Global, Market Size ($bn), 2014-2021
  • Figure 27: T2DM Therapeutics Market, North America, Treatment Patterns, 2014-2021
  • Figure 28: T2DM Therapeutics Market, North America, Annual Cost of Therapy ($), 2014-2021
  • Figure 29: T2DM Therapeutics Market, North America, Market Size ($bn), 2014-2021
  • Figure 30: T2DM Therapeutics Market, Top Five EU Countries, Treatment Usage Patterns, 2014-2021
  • Figure 31: T2DM Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2014-2021
  • Figure 32: T2DM Therapeutics Market, Top Five Countries of Europe, Market Size ($bn), 2014-2021
  • Figure 33: T2DM Therapeutics Market, Japan, Treatment Usage Patterns, 2014-2021
  • Figure 34: T2DM Therapeutics Market, Japan, Annual Cost of Therapy (ACoT) ($), 2014-2021
  • Figure 35: T2DM Therapeutics Market, Japan, Market Size ($bn), 2014-2021
  • Figure 36: T2DM Therapeutics Market, Global, Licensing Deals by Deal Value ($m), 2006-2015
  • Figure 37: T2DM Mellitus Therapeutics Market, Global, Licensing Deals by Region, 2006-2015
  • Figure 38: T2DM Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Value ($m), 2006-2014
  • Figure 39: T2DM Therapeutics Market, Global, Licensing Deals by Deal Value ($m), Upfront Payment Value ($m) and Stage of Development, 2006-2015
  • Figure 40: T2DM Therapeutics Market, Global, Licensing Deals by Stage of Development, Molecule Type and Aggregate Deal Value ($bn), 2006-2015
  • Figure 41: T2DM Therapeutics Market, Global, Licensing Deals by Molecular Target and Aggregate Deal Value ($m), 2006-2015
  • Figure 42: T2DM Therapeutics Market, Global, Co-development Deals by Value ($m), 2006-2015
  • Figure 43: T2DM Therapeutics Market, Global, Co-Development Deals by Region, 2006-2015
  • Figure 44: T2DM Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-Development Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Payment Value ($m), 2006-2014
  • Figure 45: T2DM Therapeutics Market, Global, Co-development Deals by Deal Value ($m), Upfront Payment Value ($m) and Stage of Development, 2006-2015
  • Figure 46: T2DM Therapeutics Market, Global, Co-development Deals by Stage of Development, Molecule Type and Aggregate Deal Value ($bn), 2006-2015
  • Figure 47: T2DM Therapeutics Market, Global, Co-Development Deals by Molecular Target and Aggregate Deal Value ($m), 2006-2015
Back to Top